FOSTER CITY, Calif. & MECHELEN, Belgium--(BUSINESS WIRE)-- Galapagos NV (Euronext & Nasdaq: GLPG) and Gilead Sciences (Nasdaq: GILD) today announced the decision to halt the ISABELA Phase 3 clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results